keyword
https://read.qxmd.com/read/38597542/identification-of-potential-crucial-biomarkers-in-stemi-through-integrated-bioinformatic-analysis
#1
JOURNAL ARTICLE
Li-Zhi Zhao, Yi Liang, Ting Yin, Hui-Ling Liao, Bo Liang
BACKGROUND: ST-segment elevation myocardial infarction (STEMI) is one of the leading causes of fatal cardiovascular diseases, which have been the prime cause of mortality worldwide. Diagnosis in the early phase would benefit clinical intervention and prognosis, but the exploration of the biomarkers of STEMI is still lacking. OBJECTIVES: In this study, we conducted a bioinformatics analysis to identify potential crucial biomarkers in the progress of STEMI. METHODS: We obtained GSE59867 for STEMI and stable coronary artery disease (SCAD) patients...
2024: Arquivos Brasileiros de Cardiologia
https://read.qxmd.com/read/38466536/impact-of-aml1-eto-fusion-on-the-efficacy-of-venetoclax-plus-hypomethylating-agents-in%C3%A2-newly-diagnosed-acute-myeloid-leukemia
#2
JOURNAL ARTICLE
Dian Jin, Haoguang Chen, Jingsong He, Yi Li, Gaofeng Zheng, Yang Yang, Yi Zhao, Jing Le, Wenxiu Shu, Donghua He, Zhen Cai
BACKGROUND: AML1/ETO fusion confers favorable prognosis in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). However, the impact of AML1/ETO fusion on the efficacy of venetoclax in the treatment of AML is unclear. OBJECTIVE: The aim of this study was to evaluate the efficacy of venetoclax plus hypomethylating agents (VEN/HMAs) in patients with AML1/ETO-positive AML. PATIENTS AND METHODS: Patients with newly diagnosed AML in two centers were reviewed and divided into three cohorts: AML1/ETO-positive AML treated with frontline VEN/HMA (Cohort A), AML1/ETO-negative AML treated with frontline VEN/HMA (Cohort B), or AML1/ETO-positive AML treated with frontline IC (Cohort C)...
March 11, 2024: Targeted Oncology
https://read.qxmd.com/read/38387895/-clinical-significance-of-genetic-and-molecular-changes-in-primary-myeloid-sarcoma
#3
JOURNAL ARTICLE
Ya-Jun Jiang, Chun-Fang Zhang, Hong-Xia Wang, Lan Zhao, Fei-Fei Zhang, Xiu-Hua Han
OBJECTIVE: To investigate the clinical significance of genetic and molecular changes in primary myeloid sarcoma (MS). METHODS: Fourteen patients with primary MS were selected in Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, The First People's Hospital of Lianyungang from September 2010 to December 2021. AML1-ETO fusion, PML-RARα fusion and CBFβ breakage were detected by fluorescence in situ hybridization (FISH), and the mutations of NPM1, CEBPA, FLT3, RUNX1, ASXL1, KIT and TP53 genes were detected by new generation sequencing (NGS)...
February 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38326048/-co-existence-of-aml1-eto-and-bcr-abl1-fusion-genes-in-acute-myeloid-leukemia-a-case-report
#4
JOURNAL ARTICLE
Y Q Yao, X Jia, H Liu, Q S Lu, W J Xiong, Y Zhang, Q F Liu, P C Shi
No abstract text is available yet for this article.
February 1, 2024: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://read.qxmd.com/read/38316746/efficacy-of-novel-agents-against-cellular-models-of-familial-platelet-disorder-with-myeloid-malignancy-fpd-mm
#5
JOURNAL ARTICLE
Christopher P Mill, Warren C Fiskus, Courtney D DiNardo, Patrick Reville, John A Davis, Christine E Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Lauren Flores, Xinjia Ruan, Xiaoping Su, Sanam Loghavi, Joseph D Khoury, Kapil N Bhalla
Germline, mono-allelic mutations in RUNX1 cause familial platelet disorder (RUNX1-FPD) that evolves into myeloid malignancy (FPD-MM): MDS or AML. FPD-MM commonly harbors co-mutations in the second RUNX1 allele and/or other epigenetic regulators. Here we utilized patient-derived (PD) FPD-MM cells and established the first FPD-MM AML cell line (GMR-AML1). GMR-AML1 cells exhibited active super-enhancers of MYB, MYC, BCL2 and CDK6, augmented expressions of c-Myc, c-Myb, EVI1 and PLK1 and surface markers of AML stem cells...
February 5, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38289944/a-murine-model-to-evaluate-immunotherapy-effectiveness-for-human-fanconi-anemia-mutated-acute-myeloid-leukemia
#6
JOURNAL ARTICLE
Tingting Huang, Bernice Leung, Yuyang Huang, Laura Price, Jiang Gui, Bonnie W Lau
Fanconi anemia (FA)-mutated acute myeloid leukemia (AML) is a secondary AML with very poor prognosis and limited therapeutic options due to increased sensitivity to DNA-damaging agents. PD-1 immune checkpoint inhibitors upregulate T-cell killing of cancer cells and is a class of promising treatment for FA-AML. Here, we developed a novel FA-AML murine model that allows the study of human AML with a humanized immune system in order to investigate immunotherapeutic treatments in vivo. FA-AML1 cells and non-FA-mutated Kasumi-1 cells were injected into 8-10 week old NSG mice...
2024: PloS One
https://read.qxmd.com/read/38268050/a-novel-aml1-eto-fto-positive-feedback-loop-promotes-leukemogenesis-and-ara-c-resistance-via-stabilizing-igfbp2-in-t-8-21-acute-myeloid-leukemia
#7
JOURNAL ARTICLE
Wei Zhou, Siying Li, Hong Wang, Jingfeng Zhou, Shuyi Li, Guofeng Chen, Wei Guan, Xianli Fu, Clara Nervi, Li Yu, Yonghui Li
BACKGROUND: t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subtype with a favorable prognosis, approximately 30-50% of patients experience drug resistance and subsequent relapse. N6 -methyladenosine (m6 A) is demonstrated to be involved in the development of AML. However, the regulatory mechanisms between AML1-ETO and m6 A-related enzymes and the roles of dysregulated m6 A modifications in the t(8;21)-leukemogenesis and chemoresistance remain elusive...
January 24, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38149027/chimeric-antigen-receptor-t-cell-therapy-for-acute-leukemia
#8
JOURNAL ARTICLE
Jing Pan
The worldwide use of CD19 chimeric antigen receptor (CAR)-T cells has increased the response rate in patients with refractory or relapsed B-cell acute lymphoblastic leukemia. Clinical practice has become much safer with the help of immunotherapy-related toxicity management guidelines, such as the ASTCT consensus grading system. Tocilizumab and steroids are the major interventions for controlling cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New drugs and interventions for uncontrolled CRS and ICANS, including JAK1/2 inhibitors, have also been investigated...
November 25, 2023: Blood Cell Ther
https://read.qxmd.com/read/37888866/protein-nanocaged-selenium-induces-t-8-21-leukemia-cell-differentiation-via-epigenetic-regulation
#9
JOURNAL ARTICLE
Long Fang, Ruofei Zhang, Lin Shi, Jiaying Xie, Long Ma, Yili Yang, Xiyun Yan, Kelong Fan
The success of arsenic in degrading PML-RARα oncoprotein illustrates the great anti-leukemia value of inorganics. Inspired by this, the therapeutic effect of inorganic selenium on t(8; 21) leukemia is studied, which has shown promising anti-cancer effects on solid tumors. A leukemia-targeting selenium nanomedicine is rationally built with bioengineered protein nanocage and is demonstrated to be an effective epigenetic drug for inducing the differentiation of t(8;21) leukemia. The selenium drug significantly induces the differentiation of t(8;21) leukemia cells into more mature myeloid cells...
October 27, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/37838757/single-cell-rna-sequencing-of-a-new-transgenic-t-8-21-preleukemia-mouse-model-reveals-regulatory-networks-promoting-leukemic-transformation
#10
JOURNAL ARTICLE
Ming Yan, Mengdan Liu, Amanda G Davis, Samuel A Stoner, Dong-Er Zhang
T(8;21)(q22;q22), which generates the AML1-ETO fusion oncoprotein, is a common chromosomal abnormality in acute myeloid leukemia (AML) patients. Despite having favorable prognosis, 40% of patients will relapse, highlighting the need for innovative models and application of the newest technologies to study t(8;21) leukemogenesis. Currently, available AML1-ETO mouse models have limited utility for studying the pre-leukemic stage because AML1-ETO produces mild hematopoietic phenotypes and no leukemic transformation...
October 14, 2023: Leukemia
https://read.qxmd.com/read/37803854/-clinical-features-and-prognosis-of-core-binding-factor-acute-myeloid-leukemia-children-in-south-china-a-multicenter-study
#11
JOURNAL ARTICLE
B Y Guo, Y Wang, J Li, C F Li, X Q Feng, M C Zheng, S X Liu, L H Yang, H Jiang, H G Xu, X L He, H Wen
Objective: To analyze the clinical features, efficacy and prognosis factors of core binding factor (CBF) acute myeloid leukemia (AML) children in South China. Methods: This was a retrospective cohort study. Clinical data of 584 AML patients from 9 hospitals between January 2015 to December 2020 was collected. According to fusion gene results, all patients were divided into two groups: CBF-AML group (189 cases) and non-CBF-AML group (395 cases). CBF-AML group were divided into AML1-ETO subgroup (154 cases) and CBFβ-MYH11 subgroup (35 cases)...
October 2, 2023: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://read.qxmd.com/read/37751862/mechanisms-of-secondary-leukemia-development-caused-by-treatment-with-dna-topoisomerase-inhibitors
#12
REVIEW
Nikolai A Lomov, Vladimir S Viushkov, Mikhail A Rubtsov
Leukemia is a blood cancer originating in the blood and bone marrow. Therapy-related leukemia is associated with prior chemotherapy. Although cancer therapy with DNA topoisomerase II inhibitors is one of the most effective cancer treatments, its side effects include development of secondary leukemia characterized by the chromosomal rearrangements affecting AML1 or MLL genes. Recurrent chromosomal translocations in the therapy-related leukemia differ from chromosomal rearrangements associated with other neoplasias...
July 2023: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/37726322/effects-of-low-dose-ionizing-radiation-on-genomic-instability-in-interventional-radiology-workers
#13
JOURNAL ARTICLE
Dominika Kochanova, Sachin Gulati, Matus Durdik, Lukas Jakl, Pavol Kosik, Milan Skorvaga, Katarina Vrobelova, Katarina Vigasova, Eva Markova, Dusan Salat, Andrej Klepanec, Igor Belyaev
Interventional radiologists are chronically exposed to low-dose ionizing radiation (IR), which may represent a health risk. The aim of the present study was to evaluate genomic instability by analyzing chromosomal aberrations, micronuclei, and 53BP1 DNA repair foci in peripheral blood lymphocytes of radiologists. Based on the IAEA guidelines on biodosimetry using dicentrics, the average protracted whole-body dose in radiologists were estimated. Since preleukemic fusion genes (PFG) are the primary events leading to leukemia, we also studied their presence by RT-qPCR and FISH...
September 19, 2023: Scientific Reports
https://read.qxmd.com/read/37686475/minimal-infiltrative-disease-identification-in-cryopreserved-ovarian-tissue-of-girls-with-cancer-for-future-use-a-systematic-review
#14
REVIEW
Monika Grubliauskaite, M E Madeleine van der Perk, Annelies M E Bos, Annelot J M Meijer, Zivile Gudleviciene, Marry M van den Heuvel-Eibrink, Jelena Rascon
BACKGROUND: Ovarian tissue cryopreservation and transplantation are the only available fertility techniques for prepubertal girls with cancer. Though autotransplantation carries a risk of reintroducing malignant cells, it can be avoided by identifying minimal infiltrative disease (MID) within ovarian tissue. METHODS: A broad search for peer-reviewed articles in the PubMed database was conducted in accordance with PRISMA guidelines up to March 2023. Search terms included 'minimal residual disease', 'cryopreservation', 'ovarian', 'cancer' and synonyms...
August 22, 2023: Cancers
https://read.qxmd.com/read/37666382/safety-of-ovarian-cryopreservation-and-transplantation-in-patients-with-acute-leukemia-a-case-series
#15
JOURNAL ARTICLE
Murat Sönmezer, Yavuz Emre Şükür, Koray Görkem Saçinti, Sinan Özkavukçu, Duygu Kankaya, Cem Somer Atabekoğlu, Güldane Cengiz Seval, Kutluk H Oktay
BACKGROUND: With increased success, ovarian tissue cryopreservation has recently become a standard technique for fertility preservation. However, malignant cell introduction through ovarian tissue transplantation remains a major concern for patients with acute leukemias. OBJECTIVE: To investigate the safety of performing autologous ovarian tissue transplantation in acute leukemia survivors. STUDY DESIGN: Clinical, histopathological and molecular data of four women with acute myeloid leukemia and two with acute lymphoblastic leukemia, who underwent ovarian tissue cryopreservation and transplantation were analyzed in this case series...
September 2, 2023: American Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/37643244/il-33-st2-signaling-promotes-stemness-in-subtypes-of-myeloid-leukemia-cells-through-the-wnt-and-notch-pathways
#16
JOURNAL ARTICLE
Pascal Naef, Ramin Radpour, Carla A Jaeger-Ruckstuhl, Nils Bodmer, Gabriela M Baerlocher, Hartmut Doehner, Konstanze Doehner, Carsten Riether, Adrian F Ochsenbein
Cell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia cells in a subtype-specific manner...
August 29, 2023: Science Signaling
https://read.qxmd.com/read/37608570/regulation-of-epithelial-cell-differentiation-by-the-ubiquitous-expressed-transcript-isoform-1-in-ulcerative-colitis
#17
JOURNAL ARTICLE
Wu Peng, Chengcheng Zeng, Jing Xu, Hailan Zhao, Qingqing Zhu, Haoming Xu, Huiting Chen, Hongli Huang, Yongjian Zhou, Chong Zhao
BACKGROUND AND AIM: Mucosal healing has emerged as a desirable treatment goal for patients with ulcerative colitis (UC). Healing of mucosal wounds involves epithelial cell proliferation and differentiation, and Y-box transcription factor ZONAB has recently been identified as the key modulator of intestinal epithelial restitution. METHODS: We studied the characteristics of UXT-V1 expression in UC patients using immunohistochemistry and qPCR. The functional role of UXT-V1 in the colonic epithelium was investigated using lentivirus-mediated shRNA in vitro and ex vivo...
August 22, 2023: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/37591621/core-binding-factor-abnormalities-involving-chromosome-16-in-acute-myeloid-leukaemia-prognostic-and-therapeutic-implications
#18
JOURNAL ARTICLE
Chinmayee Panigrahi, Nakul Tikare, Prabodha Kumar Das, Somanath Padhi
Core-binding factor (CBF) abnormality-associated myeloid neoplasms incorporate acute myeloid leukaemia (AML) (CBF-AML) with translocation t(8;21)(q22;q22.1) ( AML1/ETO fusion) and inv(16)(p13.1q22) or translocation t(16;16)(p13.1;q22) ( CBFB/MYH11 fusion) abnormalities which confer a favourable prognosis following cytarabine-based induction chemotherapy. Accumulating evidence from the molecular studies have stratified CBF-AML into favourable and unfavourable subgroups based on the associated cooperating mutations that impact the outcome...
August 17, 2023: BMJ Case Reports
https://read.qxmd.com/read/37550185/-establishment-of-leukemia-cell-model-with-inducible-aml1-eto-expression-and-its-effect-on-fatty-acid-metabolism-in-leukemia-cells
#19
JOURNAL ARTICLE
W Q Xie, X Yang, R X Gu, Z Tian, H Y Xing, K J Tang, Q Rao, S W Qiu, M Wang, J X Wang
Objective: To investigate the effect of the AML1-ETO (AE) fusion gene on the biological function of U937 leukemia cells by establishing a leukemia cell model that induces AE fusion gene expression. Methods: The doxycycline (Dox) -dependent expression of the AE fusion gene in the U937 cell line (U937-AE) were established using a lentivirus vector system. The Cell Counting Kit 8 methods, including the PI and sidanilide induction, were used to detect cell proliferation, cell cycle-induced differentiation assays, respectively...
May 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/37500079/selection-of-aptamers-using-%C3%AE-1-3-glucan-recognition-protein-tagged-proteins-and-curdlan-beads
#20
JOURNAL ARTICLE
Kazuyuki Kumagai, Hiroki Okubo, Ryo Amano, Tomoko Kozu, Masanori Ochiai, Masataka Horiuchi, Taiichi Sakamoto
RNA aptamers are nucleic acids that are obtained using the systematic evolution of ligands by exponential enrichment (SELEX) method. When using conventional selection methods to immobilise target proteins on matrix beads using protein tags, sequences are obtained that bind not only to the target proteins, but also to the protein tags and matrix beads. In this study, we performed SELEX using β-1,3-glucan recognition protein (GRP)-tags and curdlan beads to immobilise the AML1 Runt domain (RD) and analysed the enrichment of aptamers using high-throughput sequencing...
July 27, 2023: Journal of Biochemistry
keyword
keyword
14554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.